A Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera

Simple item page
dc.contributor.authorFevzi Altuntaş
dc.contributor.authorMustafa Merter
dc.contributor.authorMEHMET ALI ERKURT
dc.contributor.authorISMET AYDOGDU
dc.contributor.authorMURAT ALBAYRAK
dc.contributor.authorSibel Hacioglu
dc.contributor.authorMehmet Hilmi Doğu
dc.contributor.authorABDULKADIR BASTURK
dc.contributor.authorOmer Ekinci
dc.contributor.authorFadime Ersoy Dursun
dc.contributor.authorSİNAN DEMİRCİOĞLU
dc.contributor.authorANIL TOMBAK
dc.contributor.authorIstemi SERIN
dc.contributor.authorGulsum Akgun Cagliyan
dc.contributor.authorMERİH REİS ARAS
dc.contributor.authorBurhan Turgut
dc.contributor.authorMETIN BAGCI
dc.contributor.authorSerdal Korkmaz
dc.contributor.authorMEHMET SİNAN DAL
dc.contributor.authorTurgay Ulas
dc.date.accessioned2025-04-14T05:52:19Z
dc.date.available2025-04-14T05:52:19Z
dc.date.issued2023
dc.description.abstractIntroduction: Ruxolitinib is a small -molecule inhibitor of the JAK1/2 pathway. This study aimed to reveal the results and side-effect profile of the use of ruxolitinib as a treatment option in polycythemia vera (PV). Methods: A total of 34 patients with PV from 18 different centers were included in the study. The evaluation of the response under treatment with ruxolitinib was determined as a reduction in spleen volume (splenomegaly size: ≥35%) by imaging and control of hematocrit levels (≤45%) compared to baseline. Results: While the number of patients in which a reduction in spleen volume and hematocrit control was achieved was 19 (55.9%) at 3 months of treatment, it was 21 (61.8%) at 6 months. Additionally, while the number of side effects was negatively correlated with the reduction in spleen volume (Spearman’s rho: -0.365, p=0.034), a decrease in the hematocrit level was positively correlated (Spearman’s rho: 0.75, p=0.029). Those without a reduction in spleen volume experienced more constipation (chi-square: 5.988, Fisher’s exact test: p=0.033). Conclusion: This study shed light on the use of ruxolitinib in PV and the importance of splenomegaly on studies planned with larger patient groups.
dc.identifier.DOI-ID10.4274/imj.galenos.2023.66742
dc.identifier.urihttp://hdl.handle.net/20.500.14701/55240
dc.language.isoİngilizce
dc.subjectTıbbi Araştırmalar Deneysel
dc.subjectKadın Hastalıkları ve Doğum
dc.subjectGenel ve Dahili Tıp
dc.subjectOnkoloji
dc.titleA Real-Life Turkish Experience of Ruxolitinib in Polycythemia Vera

Files

Collections

TR-Dizin Koleksiyonu